These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 7911565

  • 1. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.
    Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ.
    Oncogene; 1994 Jul; 9(7):1829-38. PubMed ID: 7911565
    [Abstract] [Full Text] [Related]

  • 2. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
    Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ.
    Oncogene; 1998 Oct 29; 17(17):2235-49. PubMed ID: 9811454
    [Abstract] [Full Text] [Related]

  • 3. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene.
    Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ, Slamon DJ.
    Cancer Res; 1999 Mar 15; 59(6):1347-55. PubMed ID: 10096569
    [Abstract] [Full Text] [Related]

  • 4. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair.
    Arteaga CL, Winnier AR, Poirier MC, Lopez-Larraza DM, Shawver LK, Hurd SD, Stewart SJ.
    Cancer Res; 1994 Jul 15; 54(14):3758-65. PubMed ID: 7913407
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
    Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, Danyluk J, Godolphin W, Sliwkowski M, Akita R.
    Cancer Res; 1993 Oct 15; 53(20):4960-70. PubMed ID: 8104689
    [Abstract] [Full Text] [Related]

  • 7. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
    Yu D, Wolf JK, Scanlon M, Price JE, Hung MC.
    Cancer Res; 1993 Feb 15; 53(4):891-8. PubMed ID: 8094034
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway.
    Ueno NT, Bartholomeusz C, Herrmann JL, Estrov Z, Shao R, Andreeff M, Price J, Paul RW, Anklesaria P, Yu D, Hung MC.
    Clin Cancer Res; 2000 Jan 15; 6(1):250-9. PubMed ID: 10656456
    [Abstract] [Full Text] [Related]

  • 12. HER-2/neu oncogene expression and proliferation in breast cancers.
    Bacus SS, Ruby SG, Weinberg DS, Chin D, Ortiz R, Bacus JW.
    Am J Pathol; 1990 Jul 15; 137(1):103-11. PubMed ID: 1973597
    [Abstract] [Full Text] [Related]

  • 13. Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu.
    Yu D, Matin A, Xia W, Sorgi F, Huang L, Hung MC.
    Oncogene; 1995 Oct 05; 11(7):1383-8. PubMed ID: 7478560
    [Abstract] [Full Text] [Related]

  • 14. The role of the HER-2/neu oncogene in gynecologic cancers.
    Cirisano FD, Karlan BY.
    J Soc Gynecol Investig; 1996 Oct 05; 3(3):99-105. PubMed ID: 8796816
    [Abstract] [Full Text] [Related]

  • 15. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.
    Ross JS, Fletcher JA.
    Stem Cells; 1998 Oct 05; 16(6):413-28. PubMed ID: 9831867
    [Abstract] [Full Text] [Related]

  • 16. Intracellular coexpression of epidermal growth factor receptor, Her-2/neu, and p21ras in human breast cancers: evidence for the existence of distinctive patterns of genetic evolution that are common to tumors from different patients.
    Shackney SE, Pollice AA, Smith CA, Janocko LE, Sweeney L, Brown KA, Singh SG, Gu L, Yakulis R, Lucke JF.
    Clin Cancer Res; 1998 Apr 05; 4(4):913-28. PubMed ID: 9563885
    [Abstract] [Full Text] [Related]

  • 17. Radiolabeled antibody targeting of the HER-2/neu oncoprotein.
    De Santes K, Slamon D, Anderson SK, Shepard M, Fendly B, Maneval D, Press O.
    Cancer Res; 1992 Apr 01; 52(7):1916-23. PubMed ID: 1348016
    [Abstract] [Full Text] [Related]

  • 18. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.
    Hengstler JG, Lange J, Kett A, Dornhöfer N, Meinert R, Arand M, Knapstein PG, Becker R, Oesch F, Tanner B.
    Cancer Res; 1999 Jul 01; 59(13):3206-14. PubMed ID: 10397267
    [Abstract] [Full Text] [Related]

  • 19. Determination of HER-2/neu amplification and expression in tumor tissue and cultured cells using a simple, phenol free method for nucleic acid isolation.
    Kury FD, Schneeberger C, Sliutz G, Kubista E, Salzer H, Medl M, Leodolter S, Swoboda H, Zeillinger R, Spona J.
    Oncogene; 1990 Sep 01; 5(9):1403-8. PubMed ID: 1699198
    [Abstract] [Full Text] [Related]

  • 20. Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status.
    Brodowicz T, Kandioler D, Tomek S, Ludwig C, Rudas M, Kunstfeld R, Koestler W, Hejna M, Budinsky A, Wiltschke C, Zielinski CC.
    Br J Cancer; 2001 Nov 30; 85(11):1764-70. PubMed ID: 11742500
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.